罕见癌症的众包治疗

• 作 者: Jeremy Cherfas 王浩鑫 马建华
• 机 构: 罗马国际生物多样性协会,
• 出 处: 科学观察
• 发表日期: 2012年04期
• 关键词: 哈佛医学院 药品开发 软件开发 生物医学 布罗莫结构域 众包 癌症研究所 靶向 被引频次 多发性骨髓瘤

至少在某些领域,生物医学已经迅速开始模仿源自软件开发的开源模式。但是,很难想象药物开发领域的开源模式是什么样子。毕竟,医药产业主要是利益驱动的,这也是美国FDA的罕见病药品开发办公室为业界提供额外激励的原因之一。如果不能确定利润在哪里,有谁会对此开展研究呢?然而,一些实验室却逆流而上,哈佛医学院Dana-Farber癌症研究所的James E.Bradner小组就是其中的佼佼者。Bradner成功地使用了开源策略对付癌症,动力则来

At least in some areas, biomedicine has rapidly begun to mimic the open source paradigm that stems from software development. However, it is hard to imagine what the open source model for drug development would look like. After all, the pharmaceutical industry is primarily profit-driven and is one of the reasons the FDA’s Rare Drug Development Office provides additional incentives for the industry. If you are not sure where your profits are, who will do the research? However, some labs go counter-current, with the James E. Bradner team at the Dana-Farber Cancer Institute at Harvard Medical School among the best. Bradner has successfully used the open source strategy to fight cancer, power comes